Аденомы гипофиза: современные принципы диагностики и лечения

В обзоре систематизированы знания о лечении пациентов с аденомами гипофиза. Аденомы гипофиза составляют 15 % от общего числа интракраниальных опухолей, занимая 3-е место по частоте после менингиом и глиом головного мозга. К настоящему времени проведены многочисленные исследования этой патологии. Разработаны международные алгоритмы диагностики и лечения аденом гипофиза с различной гормональной активностью, включающие применение медикаментозных, хирургических и лучевых методов.

1. Aflorei E.D., Korbonits M. Epidemiology and etiopathogenesis of pituitary adenomas. J Neurooncol 2014;117:379-94. DOI: 10.1007/s11060-013-1354-5

2. Cortet-Rudelli C., Bonneville J.-F., Borson-Chazot F. et al. Post-surgical management of non-functioning pituitary adenoma. Ann Endocrinol (Paris) 2015;76:228-38. DOI: 10.1016/j.ando.2015.04.003.

3. Chanson P., Raverot G., Castinetti F. et al. Management of clinically non-functioning pituitary adenoma. Ann Endocrinol (Paris) 2015;76:239-47. DOI: 10.1016/j.ando.2015.04.002.

4. Oki Y. Medical management of functioning pituitary adenoma: an update. Neurol Med Chir (Tokyo) 2014;54:958-65. DOI: 10.2176/nmc.ra.2014-0239.

5. Okafor U., Onwuekwe I., Ezegwui H. Management of pituitary adenoma with mass effect in pregnancy: a case report. Cases J 2009;2:9117. DOI: 10.1186/1757-1626-2-9117.

6. Patterson R.H. The role of transcranial surgery in the management of pituitary adenoma. In: Modern neurosurgery of meningiomas and pituitary adenomas. Vienna: Springer, 1996. Pp. 16, 17. DOI: 10.1007/978-3-7091-9450-8_6.

7. Azab M.A., O’Hagan M., Abou-Al-Shaar H. et al. Safety and outcome of transsphenoidal pituitary adenoma resection in elderly patients. World Neurosurg 2019;122:e1252-8. DOI: 10.1016/j.wneu.2018.11.024.

8. Астафьева Л.И., Кадашев Б.А., Шишкина Л.В. и др. Клинико-морфологические характеристики, диагностические критерии и результаты хирургического лечения ТТГ-секрети-рующих аденом гипофиза. Журнал «Вопросы нейрохирургии» им. Н.Н. Бурденко 2016;80(6):24-35. DOI: 10.17116/neiro201680624-35.

9. Астафьева Л.И., Кадашев Б.А., Калинин П.Л. и др. Клинические синдромы сдавленного и хирургически пересеченного стебля гипофиза. Проблемы эндокринологии 2018;64(1):4—13.

10. Астафьева Л.И., Калинин П.Л., Када-шев Б.А. Современная диагностика и послеоперационный мониторинг пациентов с акромегалией в условиях нейрохирургической клиники. Журнал «Вопросы нейрохирургии» им. Н.Н. Бурденко 2017;81:58-62.

11. Калинин П.Л., Трунин Ю.Ю., Фомичев Д.В. и др. Агрессивные аденомы гипофиза (обзор литературы и клиническое наблюдение). Опухоли головы и шеи 2017;7:74-80. DOI: 10.17650/2222-1468-2017-7-4-846.

12. Калинин П.Л., Шкарубо А.Н., Астафьева Л.И. и др. Назальная ликворея при первичном лечении больших и гигантских пролактином агонистами дофамина. Журнал «Вопросы нейрохирургии» им. Н.Н. Бурденко 2017;81(6): 32-9. DOI: 10.17116/neiro201781632-39.

13. Калинин П.Л., Фомичев Д.В., Кутин М.А. и др. Эндоскопическая эндоназальная хирургия аденом гипофиза (опыт 1700 операций). Журнал «Вопросы нейрохирургии» им. Н.Н. Бурденко 2012;76:26-33.

14. Калинин П.Л., Кадашев Б.А., Фомичев Д.В. и др. Хирургическое лечение аденом гипофиза. Журнал «Вопросы нейрохирургии» им. Н.Н. Бурденко 2017;(1):95-107. DOI: 10.17116/neiro201780795-107.

15. Lloyd R.V., Osamura R.Y, Kloppel G. et al. WHO classification of tumours of endocrine organ. 4th edn. Lyon: IARC, 2017.

16. DeLellis R.A. WHO Classification of tumours. Pathology and genetics of tumours of endocrine organs. 3rd edn. Lyon: IARC Press, 2004.

17. Inoshita N., Nishioka H. The 2017 WHO classification of pituitary adenoma: overview and comments. Brain Tumor Pathol 2018;35:51-6. DOI: 10.1007/s10014-018-0314-3.

18. Lopes M.B.S. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 2017;134:521-35. DOI: 10.1007/s00401-017-1769-8.

19. Nishioka H., Inoshita N., Mete O. et al. The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol 2015;26:349-55. DOI: 10.1007/s12022-015-9398-z.

20. 0ystese K.A., Casar-Borota O., Normann K.R. et al. Estrogen receptor a, a sex-dependent predictor of aggressiveness in nonfunctioning pituitary adenomas: SSTR and sex hormone receptor distribution in NFPA. J Clin Endocrinol Metab 2017;102:3581-90. DOI: 10.1210/jc.2017-00792.

21. Mete O., Asa S.L. Clinicopathological correlations in pituitary adenomas. Brain Pathol 2012;22:443-53. DOI: 10.1111/j.1750-3639.2012.00599.x.

22. Ezzat S., Asa S.L., Couldwell W.T. et al. The prevalence of pituitary adenomas. Cancer 2004;101:613-9. DOI: 10.1002/cncr.20412.

23. Lim C.T., Korbonits M. Update on the clinicopathology of pituitary adenomas. Endocr Pract 2018;24:473-88. DOI: 10.4158/EP-2018-0034.

24. Galland F., Vantyghem M.-C., Cazabat L. et al. Management of nonfunctioning pituitary incidentaloma. Ann Endocrinol (Paris) 2015;76:191-200. DOI: 10.1016/j.ando.2015.04.004.

25. Кадашев Б.А. Аденомы гипофиза: клиника, диагностика, лечение. Тверь: Триада, 2007.

26. Agustsson T.T., Baldvinsdottir T., Jonasson J.G. et al. The epidemiology of pituitary adenomas in Iceland, 19552012: a nationwide population-based study. Eur J Endocrinol 2015;173:655-64. DOI: 10.1530/EJE-15-0189.

27. Gruppetta M., Mercieca C., Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 2013;16:545-53. DOI: 10.1007/s11102-012-0454-0.

28. Fernandez A., Karavitaki N., Wass J.A.H. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010;72:377-82. DOI: 10.1111/j.1365-2265.2009.03667.x.

29. Kane L.A., Leinung M.C., Scheithauer B.W. et al. Pituitary adenomas in childhood and adolescence. J Clin Endocrinol Metab 1994;79:1135-40. DOI: 10.1210/jcem.79.4.7525627.

30. Molitch M.E. Diagnosis and treatment of pituitary adenomas. JAMA 2017;317:516. DOI: 10.1001/jama.2016.19699.

31. Hall W.A. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994;120:817. DOI: 10.7326/0003-4819120-10-199405150-00001.

32. Vernooij M.W., Ikram M.A., Tanghe H.L. et al. Incidental findings on brain MRI in the general population. N Engl J Med 2007;357:1821-8. DOI: 10.1056/NEJMoa070972.

33. Raappana A., Koivukangas J., Ebeling T. et al. Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab 2010;95:4268-75. DOI: 10.1210/jc.2010-0537.

34. Vroonen L., Daly A.F., Beckers A. Epidemiology and management challenges in prolactinomas. Neuroendocrinology 2019;109:20-7. DOI: 10.1159/000497746.

35. Melmed S., Cook D., Schopohl J. et al. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 2010;13:18-28. DOI: 10.1007/s11102-009-0191-1.

36. Daly A.F., Rixhon M., Adam C. et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006;91:4769-75. DOI: 10.1210/jc.2006-1668.

37. Fontana E., Gaillard R. [Epidemiology of pituitary adenoma: results of the first Swiss study]. Rev Med Suisse 2009;5:2172-4.

38. Molitch M.E. Nonfunctioning pituitary tumors. Handb Clin Neurol 2014;124:167-84. DOI: 10.1016/B978-0-444-59602-4.00012-5.

39. Sievers C., Ising M., Pfister H. et al. Personality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and age- and gender-matched controls. Eur J Endocrinol 2009;160:367-73. DOI: 10.1530/EJE-08-0896.

40. Dekkers O.M., van der Klaauw A.A., Pereira A.M. et al. Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2006;91:3364-9. DOI: 10.1210/jc.2006-0003.

41. Biermasz N.R., Joustra S.D., Donga E. et al. Patients previously treated for nonfunctioning pituitary macroadenomas have disturbed sleep characteristics, circadian movement rhythm, and subjective sleep quality. J Clin Endocrinol Metab 2011;96:1524-32. DOI: 10.1210/jc.2010-2742.

42. Brummelman P., Elderson M.F., Dullaart R.P.F. et al. Cognitive functioning in patients treated for nonfunctioning pituitary macroadenoma and the effects of pituitary radiotherapy. Clin Endocrinol (Oxf) 2011;74:481-7. DOI: 10.1111/j.1365-2265.2010.03947.x.

43. Koktekir E., Karabagli H., Ozturk K. Simultaneous transsphenoidal and transventricular endoscopic approaches for giant pituitary adenoma with hydrocephalus. J Craniofac Surg 2015;26:e39-42. DOI: 10.1097/SCS.0000000000001298.

44. Joshi S.M., Chopra I.S., Powell M. Hydrocephalus caused by giant pituitary tumors: case series and guidelines for management. Br J Neurosurg 2009;23:30-2. DOI: 10.1080/02688690802535081.

45. Scarone P., Losa M., Mortini P. et al. Obstructive hydrocephalus and intracranial hypertension caused by a giant macroprolactinoma. Prompt response to medical treatment. J Neurooncol 2006;76:51-4. DOI: 10.1007/s11060-005-2319-0.

46. Корниенко В., Пронин И. Диагностическая нейрорадиология. Т. 2. М., 2009.

47. Bashari W.A., Senanayake R., Fernandez-Pombo A. et al. Modern imaging of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 2019;33:101278. DOI: 10.1016/j.beem.2019.05.002.

48. Yuh W.T., Fisher D.J., Nguyen H.D. et al. Sequential MR enhancement pattern in normal pituitary gland and in pituitary adenoma. Am J Neuroradiol 1994;15:101-8.

49. Chaudhary V., Bano S. Imaging of the pituitary: recent advances. Indian J Endocrinol Metab 2011;15:216. DOI: 10.4103/2230-8210.84871.

50. Masopust V., Netuka D., Benes V. et al. Magnetic resonance imaging and histology correlation in Cushing’s disease. Neurol Neurochir Pol 2017;51:45-52. DOI: 10.1016/j.pjnns.2016.10.005.

51. Grober Y., Grober H., Wintermark M. et al. Comparison of MRI techniques for detecting microadenomas in Cushing’s disease. J Neurosurg 2018;128:1051-7. DOI: 10.3171/2017.3.JNS163122.

52. Argyropoulou M., Kiortsis D. Magnetization transfer imaging of the pituitary gland. Hormones 2003;2:98-102. DOI: 10.14310/horm.2002.1188.

53. Knosp E., Steiner E., Kitz K. et al. Pituitary adenomas with invasion of the cavernous sinus space. Neurosurgery 1993;33:610-8. DOI: 10.1227/00006123199310000-00008.

54. Micko A.S.G., Wohrer A., Wolfsberger S. et al. Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg 2015;122:803-11. DOI: 10.3171/2014.12.JNS141083.

55. Hisanaga S., Kakeda S., Yamamoto J. et al. Pituitary macroadenoma and visual impairment: postoperative outcome prediction with contrast-enhanced FIESTA. Am J Neuroradiol 2017;38:2067-72. DOI: 10.3174/ajnr.A5394.

56. Kunii N., Abe T., Kawamo M. et al. Rathke’s cleft cysts: differentiation from other cystic lesions in the pituitary fossa by use of single-shot fast spin-echo diffusion-weighted MR imaging. Acta Neurochir (Wien) 2007;149:759-69. DOI: 10.1007/s00701-007-1234-x.

57. Hassan H.A., Bessar M.A., Herzallah I.R. et al. Diagnostic value of early postoperative MRI and diffusion-weighted imaging following trans-sphenoidal resection of non-functioning pituitary macroadenomas. Clin Radiol 2018;73:535-41. DOI: 10.1016/j.crad.2017.12.007.

58. Wang M., Liu H., Wei X. et al. Application of reduced-FOV diffusion-weighted imaging in evaluation of normal pituitary glands and pituitary macroadenomas. Am J Neuroradiol 2018;39:1499-504. DOI: 10.3174/ajnr.A5735.

59. Buttrick S., Morcos J.J., Elhammady M.S. et al. Extradural clinoidectomy for resection of clinoidal meningioma. Neurosurg Focus 2017;43:V10. DOI: 10.3171/2017.10.FocusVid.17363.

60. Yang B.T., Chong V.F.H., Wang Z.C. et al. Sphenoid sinus ectopic pituitary adenomas: CT and MRI findings. Br J Radiol 2010;83:218-24. DOI: 10.1259/bjr/76663418.

61. Sakai N., Yamashita S., Takehara Y. et al. Evaluation of the antiangiogenic effects of octreotide on growth hormone-producing pituitary adenoma using arterial spin-labeling perfusion imaging. Magn Reson Med Sci 2015;14:73-6. DOI: 10.2463/mrms.2014-0026.

62. Shults E.I., Pronin I.N., Kalinin P.L. et al. SCT perfusion in the diagnosis of sellar and parasellar tumors. Zhurnal “Voprosy neyrokhirurgii” im. N.N. Burdenko = Burdenko's Journal of Neurosurgery 2015;79:71. DOI: 10.17116/neiro201579471-77.

63. Pany A., Sobri M., Valarmathi S. et al. Giant aneurysm or pituitary macroadenoma: a diagnostical misconstrue. Med J Malaysia 2004;59:123-5.

64. Lamback E.B., Gouveia H.R., Bulzico D.A. Into the void: a giant aneurysm mimicking a macroprolactinoma. Endocrine 2017;58:394-5. DOI: 10.1007/s12020-017-1419-x.

65. Martin A.J., Hetts S.W., Dillon W.P. et al. MR imaging of partially thrombosed cerebral aneurysms: characteristics and evolution. Am J Neuroradiol 2011;32:346-51. DOI: 10.3174/ajnr.A2298.

66. Orman G., Valand H.A., Huisman T.A.G.M. Advanced multimodality neuroimaging of a giant, thrombosed MCA aneurysm complicated by an acute stroke in a pediatric patient. Radiol Case Reports 2020;15:292-7. DOI: 10.1016/j.radcr.2019.12.016.

67. Григорьев А.Ю., Годков И.М., Григорьева Е.В. Трансназальное эндоскопическое удаление аденомы гипофиза у больных с расширенными межкавернозными синусами. Нейрохирургия 2015;(3):50-3.

68. Orozco L.D., Buciuc R.F., Parent A.D. Endovascular embolization of prominent intercavernous sinuses for successful transsphenoidal resection of cushing microadenoma. Oper Neurosurg 2012;71:onsE204-8. DOI: 10.1227/NEU.0b013e31825b1eac.

69. Mizutani K., Toda M., Yoshida K. Analysis of the intercavernous sinus in sellar lesions using multidetector computed tomography digital subtraction venography. World Neurosurg 2016;86:336-40. DOI: 10.1016/j.wneu.2015.08.079.

70. Stadlbauer A., Buchfelder M., Nimsky C. et al. Proton magnetic resonance spectroscopy in pituitary macroadenomas: preliminary results. J Neurosurg 2008;109:306-12. DOI: 10.3171/JNS/2008/109/8/0306.

71. Chernov M.F., Kawamata T., Amano K. et al. Possible role of single-voxel 1H-MRS in differential diagnosis of suprasellar tumors. J Neurooncol 2009;91:191-8. DOI: 10.1007/s11060-008-9698-y.

72. Losa M., Magnani P., Mortini P. et al. Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: Correlation with the effect of a single administration of octreotide on serum TSH levels. Eur J Nucl Med 1997;24:728-31. DOI: 10.1007/BF00879659.

73. D’Amico A., St^por-Fudzinska M., Tarnawski R. CyberKnife radiosurgery planning of a secreting pituitary adenoma performed with 68Ga DOTATATE PET and MRI. Clin Nucl Med 2014;39:1043-4. DOI: 10.1097/RLU.0000000000000535.

74. Yao A., Balchandani P., Shrivastava R.K. Metabolic in vivo visualization of pituitary adenomas: a systematic review of imaging modalities. World Neurosurg 2017;104:489-98. DOI: 10.1016/j.wneu.2017.04.128.

75. Feng Z., He D., Mao Z. et al. Utility of 11C-methionine and 18F-FDG PET/ CT in patients with functioning pituitary adenomas. Clin Nucl Med 2016;41:e130-4. DOI: 10.1097/RLU.0000000000001085.

76. Jones P.S., Swearingen B. Intraoperative MRI for pituitary adenomas. Neurosurg Clin N Am 2019;30:413-20. DOI: 10.1016/j.nec.2019.05.003.

77. Chittiboina P., Lalith Talagala S., Merkle H. et al. Endosphenoidal coil for intraoperative magnetic resonance imaging of the pituitary gland during transsphenoidal surgery. J Neurosurg 2016;125:1451-9. DOI: 10.3171/2015.11.JNS151465.

78. Glezer A., D’Alva C.B., Salgado L.R. et al. Pitfalls in pituitary diagnosis: peculiarities of three cases. Clin Endocrinol (Oxf) 2002;57:135-9. DOI: 10.1046/j.1365-2265.2002.01567.x.

79. Elster A.D. Sellar susceptibility artifacts: theory and implications. Am J Neuroradiol 1993;14:129-36.

80. Guo S., Cai X., Ma J. et al. Diagnosis of concomitant pituitary adenoma and Rathke’s cleft cyst with magnetic resonance imaging. Int J Surg 2015;18:191-5. DOI: 10.1016/j.ijsu.2015.05.001.

81. Takayasu T., Yamasaki F., Tominaga A. et al. A pituitary abscess showing high signal intensity on diffusion-weighted imaging. Neurosurg Rev 2006;29:246-8. DOI: 10.1007/s10143-006-0021-0.

82. Zhang X., Xing B., You H. et al. Severe ophthalmic manifestation in pituitary-involved granulomatosis with polyangiitis: a case report and literature review. BMC Ophthalmol 2018;18:299. DOI: 10.1186/s12886-018-0966-0.

83. Ben Abid F., Abukhattab M., Karim H. et al. Primary pituitary tuberculosis revisited. Am J Case Rep 2017;18:391-4. DOI: 10.12659/AJCR.903233.

84. Bonneville J.-F. Magnetic resonance imaging of pituitary tumors. Front Horm Res 2016;45:97-120. DOI: 10.1159/000442327.

85. Fenstermaker R., Abad A. Imaging of pituitary and parasellar disorders. Contin Lifelong Learn Neurol 2016;22:1574-94. DOI: 10.1212/CON.0000000000000380.

86. Morana G., Maghnie M., Rossi A. Pituitary tumors: advances in neuroimaging. In: Pediatric neuroendocrinology. Basel: Karger, 2009. Pp. 160-174. DOI: 10.1159/000262537.

87. Han S., Gao W., Jing Z. et al. How to deal with giant pituitary adenomas: transsphenoidal or transcranial, simultaneous or two-staged? J Neurooncol 2017;132:313-21. DOI: 10.1007/s11060-017-2371-6.

88. Goel A., Nadkarni T., Muzumdar D. et al. Giant pituitary tumors: a study based on surgical treatment of 118 cases. Surg Neurol 2004;61:436-45. DOI: 10.1016/j.surneu.2003.08.036.

89. Koutourousiou M., Gardner P.A., Fernandez-Miranda J.C. et al. Endoscopic endonasal surgery for giant pituitary adenomas: advantages and limitations. J Neurosurg 2013;118:621-31. DOI: 10.3171/2012.11.JNS121190.

90. Mortini P., Barzaghi R., Losa M. et al. Surgical treatment of giant pituitary adenomas. Neurosurgery 2007;60:993-1004. DOI: 10.1227/01.NEU.0000255459.14764.BA.

91. Casanueva F.F., Molitch M.E., Schlechte J.A. et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65:265-73. DOI: 10.1111/j.1365-2265.2006.02562.x.

92. Gillam M.P., Molitch M.E., Lombardi G. et al. Advances in the treatment of prolactinomas. Endocr Rev 2006;27:485-534. DOI: 10.1210/er.2005-9998.

93. Dombrowski R.C., Romeo J.H., Aron D.C. Verapamil-induced hyperprolactememia complicated by a pituitary incidentaloma. Ann Pharmacother 1995;29:999-1001. DOI: 10.1177/106002809502901009.

94. Landolt A.M., Wuthrich R., Fellmann H. Regression of pituitary prolactinoma after treatment with bromocriptine. Lancet 1979;1:1082-3.

95. Mehta G.U., Lonser R.R. Management of hormone-secreting pituitary adenomas. Neuro Oncol 2016;19:now130. DOI: 10.1093/neuonc/now130.

96. Molitch M.E. Prolactinoma in pregnancy. Best Pract Res Clin Endocrinol Metab 2011;25:885-96. DOI: 10.1016/j.beem.2011.05.011.

97. Andereggen L., Frey J., Andres R.H. et al. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas. Endocrine 2017;55:223-30. DOI: 10.1007/s12020-016-1115-2.

98. Delgrange E., Daems T., Verhelst J. et al. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 2009;160: 747-52. DOI: 10.1530/EJE-09-0012.

99. Webster J., Piscitelli G., Polli A. et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994;331:904-9. DOI: 10.1056/NEJM199410063311403.

100. Colao A., Vitale G., Cappabianca P. et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 2004;89:1704-11. DOI: 10.1210/jc.2003-030979.

101. Colao A., Di Somma C., Pivonello R. et al. Medical therapy for clinically nonfunctioning pituitary adenomas. Endocr Relat Cancer 2008;15:905-15. DOI: 10.1677/ERC-08-0181.

102. Salvatori R. Surgical treatment of microprolactinomas: pros. Endocrine 2014;47:725-9. DOI: 10.1007/s12020-014-0281-3.

103. Hu J., Zheng X., Zhang W. et al. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Pituitary 2015;18:745-51. DOI: 10.1007/s11102-014-0617-2.

104. Radoi M., Stefanescu F., Vakilnejad R. et al. Combined surgical and medical treatment of giant prolactinoma: case report. Rom Neurosurg 2016;30:200-8. DOI: 10.1515/romneu-2016-0031.

105. Pouratian N., Sheehan J., Jagannathan J. et al. Gamma Knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery 2006;59:255-66. DOI: 10.1227/01.NEU.0000223445.22938.BD.

106. Tanaka S., Link M.J., Brown P.D. et al. Gamma Knife radiosurgery for patients with prolactin-secreting pituitary adenomas. World Neurosurg 2010;74:147-52. DOI: 10.1016/j.wneu.2010.05.007.

107. Pivonello R., De Leo M., Vitale P. et al. Pathophysiology of diabetes mellitus in Cushing’s syndrome. Neuroendocrinology 2010;92:77-81. DOI: 10.1159/000314319.

108. Tomita A. [Glucocorticoid-induced osteoporosis - mechanisms and preventions (In Japanese)]. Nihon Rinsho 1998;56:1574-8.

109. Мельниченко Г.А., Дедов И.И., Белая Ж.Е. и др. Болезнь Иценко-Ку-шинга: клиника, диагностика, дифференциальная диагностика, методы лечения. Проблемы эндокринологии 2015;61:55-77. DOI: 10.14341/probl201561255-77.

110. Peck W., Dillon W., Norman D. et al. High-resolution MR imaging of pituitary microadenomas at 1.5 T: experience with Cushing disease. Am J Roentgenol 1989;152:145-51. DOI: 10.2214/ajr.152.1.145.

111. Hur K.Y., Kim J.H., Kim B.J. et al. Clinical guidelines for the diagnosis and treatment of Cushing’s disease in Korea. Endocrinol Metab 2015;30:7. DOI: 10.3803/EnM.2015.30.1.7.

112. Biller B.M.K., Grossman A.B., Stewart P.M. et al. Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2008;93:2454-62. DOI: 10.1210/jc.2007-2734.

113. Valassi E., Biller B.M.K., Swearingen B. et al. Delayed remission after transsphenoidal surgery in patients with Cushing’s disease. J Clin Endocrinol Metab 2010;95:601-10. DOI: 10.1210/jc.2009-1672.

114. Ciric I., Zhao J.-C., Du H. et al. Transsphenoidal surgery for Cushing disease. Neurosurgery 2012;70:70-81. DOI: 10.1227/NEU.0b013e31822dda2c.

115. Lodish M., Dunn S.V., Sinaii N. et al. Recovery of the hypothalamic-pituitaryadrenal axis in children and adolescents after surgical cure of Cushing’s disease. J Clin Endocrinol Metab 2012;97:1483-91. DOI: 10.1210/jc.2011-2325.

116. Petersenn S., Beckers A., Ferone D. et al. Therapy of endocrine disease: outcomes in patients with Cushing’s disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. Eur J Endocrinol 2015;172:R227-39. DOI: 10.1530/EJE-14-0883.

117. Biermasz N.R., Smit J.W.A., Pereira A.M. et al. Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients. Pituitary 2007;10:237-49. DOI: 10.1007/s11102-007-0045-7.

118. Daniel E., Aylwin S., Mustafa O. et al. Effectiveness of metyrapone in treating Cushing’s syndrome: a retrospective multicenter study in 195 Patients. J Clin Endocrinol Metab 2015;100:4146-54. DOI: 10.1210/jc.2015-2616.

119. Lo Re V., Carbonari D.M., Lewis J.D. et al. Oral azole antifungal medications and risk of acute liver injury, overall and by chronic liver disease status. Am J Med 2016;129:283-291.e5. DOI: 10.1016/j.amjmed.2015.10.029.

120. Vilar L., Naves L.A., Azevedo M.F. et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease. Pituitary 2010;13:123-9. DOI: 10.1007/s11102-009-0209-8.

121. Estrada J., Boronat M., Mielgo M. et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. N Engl J Med 1997;336:172-7. DOI: 10.1056/NEJM199701163360303.

122. Sheehan J.P., Xu Z., Salvetti D.J. et al. Results of Gamma Knife surgery for Cushing’s disease. J Neurosurg 2013;119:1486-92. DOI: 10.3171/2013.7.JNS13217.

123. Bertagna X., Guignat L. Approach to the Cushing’s disease patient with persistent/recurrent hypercortisolism after pituitary surgery. J Clin Endocrinol Metab 2013;98:1307-18. DOI: 10.1210/jc.2012-3200.

124. Nagesser S.K., van Seters A.P., Kievit J. et al. Long-term results of total adrenalectomy for Cushing’s disease. World J Surg 2000;24:108-13.

125. Biermasz N.R., Smit J.W.A., Pereira A.M. et al. Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients. Pituitary 2007;10:237-49. DOI: 10.1007/s11102-007-0045-7.

126. Dekkers O.M., Biermasz N.R., Pereira A.M. et al. Mortality in Acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008;93:61-7. DOI: 10.1210/jc.2007-1191.

127. Oshino S., Nishino A., Suzuki T. et al. Prevalence of cerebral aneurysm in patients with acromegaly. Pituitary 2013;16:195-201. DOI: 10.1007/s11102-012-0404-x.

128. Rajasoorya C., Holdaway I.M., Wrightson P. et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994; 41:95-102.

129. Katznelson L., Laws Jr. E.R., Melmed S. et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99:3933-51. DOI: 10.1210/jc.2014-2700.

130. Bello M.O., Garla V.V. Gigantism and acromegaly. In: StatPearls. Treasure Island: StatPearls Publishing, 2019. Available at: http://www.ncbi.nlm.nih.gov/pubmed/30855849.

131. Geffner M.E. The growth without growth hormone syndrome. Endocrinol Metab Clin North Am 1996;25:649-63. DOI: 10.1016/S0889-8529(05)70345-5.

132. Giustina A., Chanson P., Bronstein M.D. et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010;95: 3141-8. DOI: 10.1210/jc.2009-2670.

133. Melmed S., Casanueva F., Cavagnini F. et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005;153:737-40. DOI: 10.1530/eje.1.02036.

134. Starke R.M., Raper D.M.S., Payne S.C. et al. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab 2013;98:3190-8. DOI: 10.1210/jc.2013-1036.

135. Mercado M., Borges F., Bouterfa H. et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 2007;66:859-68. DOI: 10.1111/j.1365-2265.2007.02825.x.

136. Chanson P., Borson-Chazot F., Kuhn J.-M. et al. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf) 2008;69:299-305. DOI: 10.1111/j.1365-2265.2008.03208.x.

137. Abs R., Verhelst J., Maiter D. et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998;83:374-8. DOI: 10.1210/jcem.83.2.4556.

138. Van der Lely A.J., Biller B.M.K., Brue T. et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 2012;97:1589-97. DOI: 10.1210/jc.2011-2508.

139. Trainer P.J., Drake W.M., Katznelson L. et al. Treatment of acromegaly with the growth hormone - receptor antagonist pegvisomant. N Engl J Med 2000;342:1171-7. DOI: 10.1056/NEJM200004203421604.

140. Faglia G., Beck-Peccoz P., Piscitelli G. et al. Inappropriate secretion of thyrotropin by the pituitary. Horm Res 1987;26:79-99. DOI: 10.1159/000180687.

141. Grisoli F., Leclercq T., Winteler J.-P. et al. Thyroid-stimulating hormone pituitary adenomas and hyperthyroidism. Surg Neurol 1986;25:361-8. DOI: 10.1016/0090-3019(86)90211-9.

142. Nazato D.M., Abucham J. Diagnosis and treatment of TSH-secreting adenomas: review of a longtime experience in a reference center. J Endocrinol Invest 2018;41:447-54. DOI: 10.1007/s40618-017-0770-3.

143. Beck-Peccoz P., Persani L., Mannavola D. et al. TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab 2009;23:597-606. DOI: 10.1016/j.beem.2009.05.006.

144. Yamada S., Fukuhara N., Horiguchi K. et al. Clinicopathological characteristics and therapeutic outcomes in thyrotropinsecreting pituitary adenomas: a singlecenter study of 90 cases. J Neurosurg 2014;121:1462-73. DOI: 10.3171/2014.7.JNS1471.

145. Sanno N., Teramoto A., Osamura R.Y. Thyrotropin-secreting pituitary adenomas. Clinical and biological heterogeneity and current treatment. J Neurooncol 2001;54:179-86. DOI: 10.1023/a1012917701756.

146. Brucker-Davis F., Oldfield E.H., Skarulis M.C. et al. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab 1999;84:476-86. DOI: 10.1210/jcem.84.2.5505.

147. Amlashi F.G., Tritos N.A. Thyrotropinsecreting pituitary adenomas: epidemiology, diagnosis, and management. Endocrine 2016;52:427-40. DOI: 10.1007/s12020-016-0863-3.

148. Chanson P., Weintraub B.D., Harris A.G. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 1993;119:236-40.

149. Ness-Abramof R., Ishay A., Harel G. et al. TSH-secreting pituitary adenomas: follow-up of 11 cases and review of the literature. Pituitary 2007;10:307-10. DOI: 10.1007/s11102-007-0020-3.

150. Malchiodi E., Profka E., Ferrante E. et al. Thyrotropin-secreting pituitary adenomas: outcome of pituitary surgery and irradiation. J Clin Endocrinol Metab 2014;99:2069-76. DOI: 10.1210/jc.2013-4376.

151. Jane J.A. Jr, Laws E.R. Jr. Surgical treatment of pituitary adenomas. In: Feingold K.R., Anawalt B., Boyce A. et al. Endotext. South Dartmouth, 2000.

152. Esposito D., Olsson D.S., Ragnarsson O. et al. Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management. Pituitary 2019;22:422-34. DOI: 10.1007/s11102-019-00960-0.

153. Nomikos P., Ladar C., Fahlbusch R. et al. Impact of primary surgery on pituitary function in patients with non-functioning pituitary adenomas: a study on 721 patients. Acta Neurochir (Wien) 2004;146:27-35. DOI: 10.1007/s00701-003-0174-3.

154. Karavitaki N., Collison K., Halliday J. et al. What is the natural history of nonope-rated nonfunctioning pituitary adenomas? Clin Endocrinol (Oxf) 2007;67:938-43. DOI: 10.1111/j.1365-2265.2007.02990.x.

155. Colao A., Di Somma C., Pivonello R. et al. Medical therapy for clinically nonfunctioning pituitary adenomas. Endocr Relat Cancer 2008;15:905-15. DOI: 10.1677/ERC-08-0181.

156. Drummond J.B., Ribeiro-Oliveira A. Jr., Soares B.S. Non-functioning pituitary adenomas. In: Feingold K.R., Anawalt B., Boyce A. et al. Endotext. South Dartmouth: MDText. com, Inc., 2000-2018.